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Background: Numerous reports indicate that MDMA users consume other psychoactive drugs, among which
cannabis is one of the most common. The aim of the present study was to evaluate, using the conditioned place
preference, the effect of the cannabinoid agonist WIN 55,212-2 on the rewarding effects of MDMA in mice.
Methods: In the first experiment adolescent mice were initially conditioned with 1.25, 2.5 or 5 mg/kg of MDMA or
0.1 or 0.5 mg/kg of WIN and subsequently with both drugs. Reinstatement of the extinguished preference by
priming doses was performed in the groups that showed CPP. In the second experiment, animals were
conditioned with 2.5 or 5 mg/kg of MDMA and, after extinction, reinstatement of the preference was induced by
0.5 or 0.1 mg/kg of WIN.
Results: A low dose of WIN 55212-2 (0.1 mg/kg) increased the rewarding effects of low doses of MDMA (1.25 mg/
kg), although a decrease in the preference induced by MDMA (5 and 2.5 mg/kg) was observed when the dose of
WIN 55212-2 was raised (0.5 mg/kg). The CB1 antagonist SR 141716 also increased the rewarding effects of the
lowest MDMA dose and did not block the effects of WIN. Animals treated with the highest WIN dose plus a non-
neurotoxic dose of MDMA exhibited decreases of striatal DA and serotonin in the cortex. On the other hand, WIN
55212-2-induced CPP was reinstated by priming injections of MDMA, although WIN did not reinstate the MDMA-
induced CPP.
Conclusions: These results confirm that the cannabinoid system plays a role in the rewarding effects of MDMA
and highlights the risks that sporadic drug use can pose in terms of relapse to dependence. Finally, the potential
neuroprotective action of cannabinoids is not supported by our data; on the contrary, they are evidence of the
potential neurotoxic effect of said drugs when administered with MDMA.
Backgroud
Numerous reports indicate that MDMA users consume
other psychoactive drugs, among which cannabis is one
of the most common. Findings regarding concomitant
abuse of MDMA and cannabis are similar in different
countries, ranging from between 73% and 100% [for
review see [1,2]]. Several studies of the prolonged
combined use of MDMA and cannabis have highlighted
an association with a variety of psychological problems,
including elevated impulsiveness, anxiety and psychotic
behavior [3].
MDMA is an indirect monoaminergic agonist, [4,5].
Cannabinoids exert their effect through interactions with
specific endogenous CB1 and CB2 cannabinoid receptors
[6,7] that are present in mammalian tissues. Many of the
physiological responses provoked by MDMA are modu-
lated by the endocannabinoid system [8,9]. This system
interacts with a variety of neurotransmitters, including
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biological substrate for the addictive properties of differ-
ent drugs of abuse [11,12].
Both MDMA and cannabinoid agonists such as WIN
55212-2 (WIN) produce rewarding effects in mice
[13,14] and rats when administered alone [15]. The few
previous studies carried out to clarify the nature of the
effects of exposure to cannabinoids on MDMA abuse
liability, all of which were performed in rats, suggest
that cannabinoid agonists potentiate the rewarding
effects of MDMA [16] and that cannabinoid antagonists
exhibit an opposite action [17]. However, a recent study
by Robledo and co-workers [18] using mice has demon-
strated that THC modifies the sensitivity of these ani-
mals to the behavioral effects of MDMA in different
ways (increase/decrease) depending on the dose
employed. The complex relation between cannabinoids
and MDMA requires further study, especially regarding
the potential mutual strengthening of their rewarding
e f f e c t s .T h ea i mo ft h ep r e s e n ts t u d yw a st ou s et h e
conditioned place preference (CPP) procedure to evalu-
ate the influence of the cannabinoid agonist WIN
55212-2 on the rewarding effects of MDMA and the
reinstatement of an extinguished preference in adoles-
cent mice. This work may help to better understand the
effects of polydrug abuse, particularly as we have chosen
to study two of the most frequently used substances in
adolescents. Firstly, we studied the rewarding effects of
both drugs on the CPP and the ability of MDMA to
reinstate the extinguished preference. The doses
employed were chosen on the basis of previous work in
our laboratory [13,14]. In order to assess whether or not
the stimulation of the cannabinoid system increases the
rewarding properties of MDMA, the effects of co-
administration of WIN with rewarding and non-reward-
ing doses of MDMA were evaluated in the CPP model.
The role of the CB1 cannabinoid receptor in the poten-
tiating effects of WIN was tested using the CB1 antago-
nist SR 141716 (SR). In these experiments the ability of
a priming dose (50% of that used for conditioning) of
MDMA to reinstate the extinguished preference was
evaluated. In a second set of experiments the ability of a
priming dose of WIN to reinstate an MDMA-induced
CPP (cross-reinstatement) was tested. Additionally,
levels of brain monoamines and their metabolites were
determined in the striatum, hippocampus and cortex of
some of the experimental groups.
Methods
Subjects
Experiments were performed in a total of 265 male mice
of the OF1 strain, of 21 days of age, acquired commer-
cially from Charles River (Barcelona, Spain). They were
housed in groups of four in plastic cages (25 × 25 ×
14.5 cm) for 5 days before the experiments, under the
following conditions: constant temperature, a reversed
light schedule (white lights on: 19.30-07.30 h), and food
and water available ad libitum, except during behavioral
tests. Animals were handled over 2 days before the pre-
conditioning (Pre-C) phase commenced to reduce their
stress levels in response to experimental manipulations.
T h eC P Pb e g a no nP D2 7a n dt h eP o s t - Ct e s tw a sp e r -
formed on PD38. Procedures involving mice and their
care were conducted in compliance with national, regio-
nal and local laws and regulations, which are in accor-
dance with the European Communities Council
Directives (86/609/EEC, 24 November 1986).
Apparatus
For place conditioning, we employed eight identical
Plexiglas boxes with two equally sized compartments
(30.7 cm length × 31.5 cm width × 34.5 cm height)
separated by a gray central area (13.8 cm, length × 31.5
cm, width × 34.5 cm height). The compartments have
different color walls (black vs white) and distinct floor
textures (fine grid in the black compartment and wide
grid in the white one). Four infrared light beams in each
compartment of the box and six in the central area
allowed the recording of the position of the animal and
its crossings from one compartment to the other. The
equipment was controlled by two IBM PC computers
using MONPRE 2Z software (CIBERTEC, SA, Spain).
Drugs and experimental design
Animals were injected i.p. with 1.25, 2.5 or 5 mg/kg of
MDMA (± 3,4-methylenedioxymetamphetamine hydro-
chloride, Laboratorios Lipomed AG, Switzerland), 0.1 or
0.5 mg/kg of WIN (Tocris, Biogen Científica, S.L.,
Madrid, Spain), and 3 mg/kg of SR (Sanofi Recherche,
Montpellier, France) in a volume of 0.01 ml/g. Control
groups were injected with the physiological saline that
was used to dissolve the drugs (NaCl 0.9%) or with
Tween-80 (Sigma-Aldrich, Madrid, Spain), which was




Place conditioning consisted of three phases and took
place during the dark cycle following an unbiased proce-
dure in terms of initial spontaneous preference [for
more details see [19]]. In brief, during pre-conditioning
(Pre-C) mice were allowed access to both compartments
of the apparatus for 900 s each day for 3 days. On day
3, the time spent by the animal in each compartment
during a 900 s period was recorded. A total of 69 mice
showed a strong unconditioned aversion (less than 33%
of the session time) or preference (more than 67%) for
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Page 2 of 11one of the compartments and were, therefore, excluded
from the study: 22 exp. 1; 9 exp.2; 24 exp. 3; 4 exp. 4;
and 10 in exp. 5. In each group, half the animals
received the drug or vehicle in one compartment and
the other half in the other compartment. An ANOVA
showed that there were no significant differences in the
time spent in the drug-paired and the vehicle-paired
compartments during the pre-conditioning phase. In the
second phase (conditioning), animals were conditioned
with saline, MDMA, WIN or both drugs through four
pairings with the respective compartment (one pairing
each day). Animals received an injection of the corre-
sponding drug immediately prior to confinement in the
drug-paired compartment for 1800 s on days 4, 6, 8 and
10, and received physiological saline before being con-
fined to the vehicle-paired compartment for 1800 s on
days 5, 7, 9 and 11. During the third phase, or post-con-
ditioning (Post-C), which took place on day 12, the guil-
lotine doors separating the two compartments were
removed and the time spent by the untreated mice in
each compartment during an observation period of 900
s was recorded.
Extinction
Conditioned groups underwent a daily extinction session
which consisted of placing animals in the apparatus
(without guillotine doors separating the compartments)
for 900 s until the time spent in the drug-paired com-
partment by each group was similar to that of Pre-C
and different from that of the Post-C test. Thus, all the
animals in each group were submitted to the same num-
ber of extinction sessions, independently of their indivi-
dual scores. Saline-conditioned groups underwent only
one extinction session to confirm the lack of CPP. The
extinction of CPP was always confirmed in a subsequent
session 24 hours after the initial extinction session.
Reinstatement
The effects of a priming dose (in the first experiment
half of that used for conditioning, and in the second
experiment 0.1 or 0.5 mg/kg of WIN) were evaluated 24
hours after confirmation of extinction. The reinstate-
ment test was the same as that for Post-C (free ambula-
tion for 900 s), except that animals were tested 900 s
after administration of the respective dose of the drug.
Experiment 1: CPP induced by MDMA plus the CB1
cannabinoid agonist WIN 55212-2
To evaluate if the rewarding effects of MDMA could be
increased by the CB1 cannabinoid agonist WIN, animals
were conditioned during the conditioning phase with:
saline (SAL), 1.25, 2.5 or 5 mg/kg of MDMA (MDMA
1.25; MDMA 2.5; MDMA 5), 0.1 or 0.5 mg/kg of WIN
55212-2 (WIN 0.1, WIN 0.5), 1.25, 2.5 or 5 mg/kg of
MDMA plus 0.1 mg/kg of WIN (MDMA 1.25 + WIN
0.1; MDMA 2.5+ WIN 0.1; MDMA 5+ WIN 0.1) or
1.25, 2.5 or 5 mg/kg of MDMA plus 0.5 mg/kg of WIN
(MDMA 1.25 + WIN 0.5; MDMA 2.5+ WIN 0.5;
MDMA 5+ WIN 0.5). In the groups showing preference,
reinstatement was induced after extinction with a prim-
ing dose of MDMA (half of that used for conditioning).
In a new set of animals conditioned with saline, rein-
statement was induced with 0.6, 1.25 and 2.5 mg/kg of
MDMA.
Four new groups were employed in order to evaluate
the putative role of the CB1 cannabinoid receptor in the
potentiating effects of WIN on the MDMA-induced
CPP. During the conditioning phase, animals received 5
mg/kg of MDMA plus 3 mg/kg of SR alone or plus 0.1
mg/kg of WIN (MDMA 5 + SR 3; MDMA 5 + SR 3 +
WIN 0.1); or 1.25 mg/kg of MDMA plus 3 mg/kg of SR
alone or plus 0.1 mg/kg of WIN (MDMA 1.25 + SR 3;
MDMA 1.25 + SR 3 + WIN 0.1).
Experiment 2: Cross reinstatement by WIN 55212-2 of
MDMA-induced CPP
To evaluate if the MDMA-induced CPP was reinstated
by WIN, animals were conditioned during the condi-
tioning phase with 2.5 or 5 mg/kg of MDMA and, after
extinction, reinstatement of the preference was induced
by 0.5 or 0.1 mg/kg of WIN (MDMA 2.5-RWIN 0.5;
MDMA 5-RWIN 0.5; MDMA 2.5-RWIN 0.1; MDMA
5-RWIN 0.1; Sal-RWIN 0.1; Sal-RWIN 0.1).
Analysis of biogenic amines
Nine separate groups of animals underwent the same
schedule of treatment as applied in the conditioning ses-
sions, i.e. four injections on alternate days (intermittent
schedule) of saline (Sal), 1.25 or 5 mg/kg of MDMA
(M1.25; M5); 0,1 or 0,5 mg/kg of WIN (W 0.1; W 0.5);
and 1.25 or 5 mg/kg of MDMA plus 0,1 or 0,5 mg/kg of
WIN (M 1.25 + W 0.1; M 5 + W 0.5; M 1.25 + W 0.1
M 1.25 + W 0.1. At the time of the test, 48 hours (inter-
mittent schedule) after the last injection, mice were
sacrificed by cervical fracture. Monoamines were ana-
lyzed in a high performance liquid chromatograph (Agi-
lent 1100 series HPLC) following the methodological
procedure described in Daza-Losada et al. [14]. Dopa-
mine (DA), dihydroxyphenyl acetic acid (DOPAC) and
homovanilic acid (HVA) were analyzed in the striatum
and serotonin (5-HT), and 5-hidroxyindole acetic acid
(5-HIAA) was analyzed in the striatum, cortex and
hippocampus.
Statistical analysis
To evaluate the acquisition of CPP, the data of the time
spent by the animals in the drug-paired compartment
were analyzed with a mixed ANOVA with two between
subject variables - Dose of WIN, with three levels (0, 0.1
and 0.5), and Dose of MDMA, with three levels (1.25,
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levels (Pre-C and Post-C). Bonferroni adjustment was
employed for post hoc comparisons.
In the case of the groups which developed preference,
each of the MDMA doses employed was submitted to a
new MANOVA with one between subject variable -
“treatment”, with two levels for the doses of MDMA
1.25 and 2.5 mg/kg (M1.25+WIN0.01 and M1.25+ SR+
WIN0.1; M2.5 and M2.5 + WIN0.1) and four levels for
t h ed o s eo f5m g / k g( M 5 ,M 5 + W I N 0 . 1 ,M 5 +S R ,a n d
M5+ SR + WIN0.1) - and one within-subject variable -
“Days”, with four levels (Pre-C, Post-C, extinction and
reinstatement). In all the analyses, the Bonferroni adjust-
ment was employed to make post hoc comparisons.
In the group conditioned with 0.5 mg/kg of WIN, differ-
ences between the time spent in the drug-paired com-
partment in Pre-C and Post-C and in each extinction
session or reinstatement test were analyzed by means of
a Student’s t-test.
Similar analyses were performed in order to evaluate
the role of the CB1 receptors in the effects of WIN on
the acquisition and reinstatement of the MDMA-induced
CPP. The data of the time spent in the drug-paired com-
partment were analyzed with a mixed ANOVA with two
between subject variables - Dose of MDMA, with two
levels (1.25 and 5 mg/kg), and Cannabinoid treatment,
with three levels (Saline, SR and WIN 0.1) - and one
within variable - Days, with two levels (Pre-C and Post-
C). In the case of the groups which developed preference,
a new MANOVA was performed with one within-subject
variable: “Days”, with four levels (Pre-C, Post-C, extinc-
tion and reinstatement). Bonferroni adjustment was
employed for post hoc comparisons.
To evaluate if the MDMA-induced CPP was reinstated
by WIN, the data of the time spent in the drug-paired
compartment were analyzed with a mixed ANOVA with
two between subject variables - Dose of MDMA, with
t h r e el e v e l s( 0 ,2 . 5a n d5m g / k g ) ,a n dD o s eo fW I N ,
with three levels (0, 0.1 and 0.5 mg/kg) - and one within
variable - Days, with four levels (Pre-C, Post-C, extinc-
tion and reinstatement). Bonferroni adjustment was
employed for post hoc comparisons.
Biogenic amines were analyzed with a mixed ANOVA
with two between subject variables: MDMA dose, with
three levels (0, 1,25 and 5 mg/kg), and WIN dose, with
three levels (0, 0,1 and 0,5 mg/kg). In all the analyses,
the Bonferroni adjustment was employed for post hoc
comparisons.
Results
Experiment 1: CPP induced by MDMA and the CB1
cannabinoid agonist WIN 55212-2
The ANOVA for acquisition revealed a significant effect
of the variable Days [F(1,119) = 18.043; p < 0.001], as
more time was spent in the drug-paired compartment
during the Post-C test (p < 0.001), and the Interaction
Days × WIN × Dose of MDMA [F(6,119) = 2.454; p <
0.028]. Only the groups WIN 0.5 (Fig. 1), MDMA 1.25
+WIN 0.1 (Fig. 2), MDMA 2.5 (Fig. 3), MDMA2.5
+ W I N 0 . 1( F i g .3 ) ,M D M A5( F i g .4 ) ,a n dM D M A5 +
WIN 0.1 (Fig. 4) developed CPP, as they spent more
time in the drug-paired compartment during the Post-C
test than in the Pre-C test (p < 0.05 for MDMA 2.5 and
p < 0.02 for the rest of the groups). In the Post-C test,
significantly higher scores were obtained by the MDMA
5 group with respect to the SAL group and by the WIN
0.5 group with respect to the MDMA 1.25 + WIN 0.5
group (p < 0.05 and p < 0.02, respectively). Thus, CPP
was obtained with MDMA doses equal to or higher
than 2.5 mg/kg and with any MDMA dose plus 0.1 mg/
kg of WIN. The highest dose of WIN (0.5 mg/kg) also
induced CPP.
Among the groups showing preference, the number of
sessions required for extinction was 13 in the MDMA 5
+S R3+W I N0 . 1g r o u p ,1 1i nt h eM D M A5+W I N
0.1 group, 6 in the MDMA 2.5 + WIN 0.1 group, 3 in
the MDMA 2.5 and MDMA 5 + SR 3 groups, 4 in the
MDMA 5 group, 2 in the WIN 0.5 and MDMA 1.25 +
WIN 0.1 groups, and 1 in the MDMA 1.25 + SR 3 +
WIN 0.1 group.
The MANOVA performed for the groups in which
reinstatement was induced by 0.625 and 1.25 mg/kg of
MDMA revealed that reinstatement of this preference
was not achieved in any of the groups (Fig. 2 and 3).
The MANOVA performed for the groups in which
reinstatement was induced by 2.5 mg/kg of MDMA
(Fig. 4) revealed a significant effect of the variable Days
[F(3,52) = 14.494; p < 0.001] and the interaction Days ×
Treatment [F(12,162) = 1.866; p < 0.04], with reinstate-
ment of the preference observed in all the groups (p <
0.02 for MDMA5 and MDMA 5+ SR 3 + WIN 0.1, and
p < 0.002 for the rest of the groups) with the exception
of that conditioned with saline and treated with 2.5 mg/
k go fM D M Aa sap r i m i n gd o s e .T h u s ,o n l yi nm i c ei n
which CPP was induced with 5 mg/kg of MDMA was
reinstatement of the preference observed.
The AVOVA for the effects of SR revealed a signifi-
cant effect of the variables Days [F(1,68) = 23.206; p <
0.001], the interaction Days × Dose of MDMA [F(1,68)
= 5.621; p < 0.021], and the interaction Days × Dose of
MDMA × Cannabinoid treatment [F(2,68) = 4.536; p <
0.014]. All the groups, except MDMA 1.25, developed
CPP (p < 0.02 for MDMA 1.25 +SR 3 (Fig. 2), MDMA
1.25 +SR 3 +WIN 0.1 (Fig. 2), and MDMA 5 +SR 3
(Fig. 4); and p < 0.001 for the rest). Animals treated
with MDMA 1.25 +SR 3 or MDMA 1.25 +SR 3 +WIN
0.1 (Fig. 2) presented higher scores in the Post-C test
than those treated only with MDMA 1.25 (p < 0.003).
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Page 4 of 11Figure 1 Acquisition, extinction and reinstatement of WIN-induced CPP. Acquisition, extinction and reinstatement of WIN-induced CPP in
three groups of animals: SAL, animals receiving saline in both compartments (n = 10); WIN 0.1, WIN 0.5, animals receiving 0.1 or 0.5 mg/kg of
WIN in the drug-paired compartment (n = 10). The bars represent the mean (± SEM) time spent in the drug-paired compartment before
conditioning sessions (white bars), after conditioning sessions (orange bars), in the last extinction session (light orange bars) and in the
reinstatement test (brown). ** p < 0.02 significant difference in the time spent in pre-conditioning vs. post-conditioning sessions or
reinstatement tests.
Figure 2 Acquisition, extinction and reinstatement of 1.25 mg/kg MDMA- and WIN-induced CPP. Acquisition, extinction and
reinstatement of MDMA- and WIN-induced CPP in six groups of animals: SAL, animals receiving saline in both compartments (n = 10); MDMA
1.25, animals receiving 1.25 mg/kg of MDMA in the drug-paired compartment (n = 10); MDMA 1.25 + WIN 0.5 and MDMA 1.25 + WIN 0.1
animals receiving 0.5 or 0.1 mg/kg of WIN plus 1.25 mg/kg of MDMA in the drug-paired compartment (n = 11); MDMA 1.25 + SR 3 + WIN 0.1,
animals conditioned with 1.25 mg/kg of MDMA plus 3 mg/kg of SR plus 0.1 mg/kg of WIN (n = 14). The bars represent the mean (± SEM) time
spent in the drug-paired compartment before conditioning sessions (white bars), after conditioning sessions (blue bars), in the last extinction
session (light blue bars) and in the reinstatement test (dark blue bars). ** p < 0.02 significant difference in the time spent in pre-conditioning
vs. post-conditioning sessions or reinstatement tests.
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Page 5 of 11Figure 3 Acquisition, extinction and reinstatement of 2.5 mg/kg MDMA- and WIN-induced CPP. Acquisition, extinction and reinstatement
of MDMA- and WIN-induced CPP in four groups of animals: SAL, animals receiving saline in both compartments (n = 10); MDMA 2.5, animals
receiving 2.5 mg/kg of MDMA in the drug-paired compartment (n = 10); MDMA 2.5 + WIN 0.5 and MDMA 2.5 + WIN 0.1 animals receiving 0.5 or
0.1 mg/kg of WIN plus 2.5 mg/kg of MDMA in the drug-paired compartment (n = 11). The bars represent the mean (± SEM) time spent in the
drug-paired compartment before conditioning sessions (white bars), after conditioning sessions (blue bars), in the last extinction session (light
blue bars) and in the reinstatement test (dark blue bars). * p < 0.05; ** p < 0.02 significant difference in the time spent in pre-conditioning
vs. post-conditioning sessions or reinstatement tests.
Figure 4 Acquisition, extinction and reinstatement of 5 mg/kg MDMA- and WIN-induced CPP. Acquisition, extinction and reinstatement of
MDMA- and WIN-induced CPP in six groups of animals: SAL, animals receiving saline in both compartments (n = 10); MDMA 5, animals receiving
5 mg/kg of MDMA in the drug-paired compartment (n = 10); MDMA 5 + WIN 0.5 and MDMA 5 + WIN 0.1 animals receiving 0.5 or 0.1 mg/kg of
WIN plus 5 mg/kg of MDMA in the drug-paired compartment (n = 11); MDMA 5 + SR 3 + WIN 0.1, animals conditioned with 5 mg/kg of MDMA
plus 3 mg/kg of SR plus 0.1 mg/kg of WIN (n = 14). The bars represent the mean (± SEM) time spent in the drug-paired compartment before
conditioning sessions (white bars), after conditioning sessions (blue bars), in the last extinction session (light blue bars) and in the reinstatement
test (dark blue bars). ** p < 0.02; *** p < 0.002 significant difference in the time spent in pre-conditioning vs. post-conditioning sessions or
reinstatement tests.
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score in the Post-C test than the MDMA 1.25 group
(p < 0.001), with no differences being observed between
the other groups. In general, SR increased the reinfor-
cing effects of MDMA and did not block the effects of
WIN.
The MANOVA for the effect of SR on the reinstate-
ment of a MDMA-induced CPP revealed an effect of
the variable Days [F(3,55) = 17.814; p < 0.001] and the
interaction Days × Groups of treatment [F(4.57) =
4.697; p < 0.02], as the extinguished preference was
reinstated only in the groups conditioned wit 5 mg/kg
of MDMA (Fig. 4), regardless of the other treatment
received (p < 0.02 for MDMA 5 +SR 3, and p < 0.001
for MDMA 5 +SR 3 + WIN 0.1).
Experiment 2: Cross reinstatement of MDMA-induced CPP
by WIN 55212-2
The results obtained in Experiment 2 are represented in
Fig. 5.
The ANOVA revealed a significant effect of the vari-
able Days [F(3,56) = 9.667; p < 0.001] and the Interac-
tion Days × Dose of MDMA [F(3,56) = 217; p < 0.019],
Post-C test scores significantly higher than that of the
Pre-C test in the groups conditioned with 2.5 or 5 mg/
kg of MDMA (p < 0.05 and p < 0.02, respectively).
Reinstatement of this preference was not achieved in
any of the groups.
Brain monoamines
The ANOVA for the striatal levels of DA revealed a sig-
nificant effect of the variable MDMA dose [F(4, 49) =
3.530; p < 0.037], as lower levels of DA were detected in
the groups treated with 5 mg/kg of MDMA than in
those treated with 1.25 mg/kg of MDMA (p < 0.05).
The interaction WIN dose × MDMA dose [F(4, 49) =
2.791; p < 0.036] also had a significant effect, producing
lower concentrations of DA in the M5+WIN 0.5 group
than in the Sal and M1.25 +Win 0.5 groups (p < 0.05
and p < 0.001, respectively). No differences were
observed in the concentrations of DOPAC, HVA, sero-
tonin or 5-HIIA in the striatum (see Additional file 1).
In the cortex, serotonin levels showed a significant
effect for the variable MDMA dose [F(2,46) = 9.141; p <
0.001] and the interaction MDMA dose × WIN dose [F
(4,46) = 4.798; p < 0.003]. Groups treated with 5 or 1.25
mg/kg of MDMA plus 0.5 mg/kg of WIN exhibited
lower levels of serotonin than those treated only with
this dose of WIN (W0.5). In addition, the M1.25 + W
0.5 group displayed lower serotonin levels than the
M1.25 + W 0.1 (p < 0.002) group. The levels of 5-HIAA
in the cortex showed a signifi c a n te f f e c to ft h ev a r i a b l e
MDMA dose [F(2,45) = 5.285; p < 0.008], which was
Figure 5 Reinstatement of MDMA-induced CPP by priming injections of WIN. Reinstatement of MDMA-induced CPP by priming injections
of WIN in six groups of animals (n = 10): Sal-RWIN 0.5 and Sal-RWIN 0.1, animals conditioned with saline in the drug-paired compartment and
receiving a priming injection of 0.5 or 0.1 mg/kg of WIN; MDMA 2.5-RWIN 0.5 and MDMA 2.5-RWIN 0.1, animals conditioned with 2.5 mg/kg of
MDMA in the drug-paired compartment and receiving a priming injection of 0.5 or 0.1 mg/kg of WIN.; MDMA 5-RWIN 0.5 and MDMA 5-RWIN
0.1, animals conditioned with 5 mg/kg of MDMA in the drug-paired compartment and receiving a priming injection of 0.5 and 0.1 mg/kg of
WIN. The bars represent the mean (± SEM) time spent in the drug-paired compartment before conditioning sessions (white bars), after
conditioning sessions (pink bars), in the last extinction session (light pink bars) and in the reinstatement test (dark pink bars). * = p < 0.05, ** = p
< 0.02 significant difference in the time spent in pre-conditioning vs. post-conditioning sessions or reinstatement tests.
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(p < 0.05), and for the variable WIN dose [F(2,45) =
3.394; p < 0.04], which was also lower in the groups
receiving the highest WIN dose (0.5 mg/kg).
In the hippocampus, serotonin concentration had sig-
nificant effects on the interaction of the variables
MDMA dose × WIN dose [F(4,46) = 2.828; p < 0.03].
Animals treated with 5 mg/kg of MDMA alone (M5)
exhibited higher levels than those treated with saline
(Sal) (p < 0.05). 5-HIAA levels had significant effects on
the interaction of the variables MDMA dose × WIN
dose [F(4,44) = 3.271; p < 0.01]. In the groups treated
with MDMA (M5 and M1.25), the concentration of this
metabolite was lower than in the group treated with sal-
ine (p < 0.05). The groups treated with the lowest dose
of MDMA plus any of the WIN doses (M1.25 + W0.1
or M1.25 + W0.5) displayed higher levels of 5-HIAA
than those treated only with 1.25 mg/kg of MDMA
(M1.25) (p < 0.01).
Discussion
The results of the present study confirm the complex
interaction between the cannabinoid system and
MDMA. The cannabinoid agonist WIN 55212-2 can
increase or decrease the acquisition of MDMA-induced
CPP depending on the dose employed. The CB1 recep-
tor is not involved in the potentiating effect of WIN.
We have also observed cross-reinstatement, since
MDMA was capable of reinstating the WIN-induced
CPP. Additionally, in contrary to the presumed neuro-
protective role of cannabinoids, the present results show
that WIN 55212-2 induces a decrease in the concentra-
tions of dopamine in the striatum and serotonin in the
cortex when administered with a non-neurotoxic dose
of MDMA.
We have confirmed that MDMA is capable of indu-
c i n gC P Pe v e na tl o wd o s e s( 2 . 5m g / k g ) ,a n dt h a tr e i n -
statement of the CPP can be achieved with priming
doses 50% lower than that used for conditioning. In
addition, the CB1 agonist WIN also induced CPP with
the highest dose employed (0.5 mg/kg). Cross-reinstate-
ment was observed, since the WIN-induced preference
was reinstated after a priming dose of MDMA (5 mg/
kg). The results obtained in these experiments confirm
and extend those of a previous report by our group [14].
On the other hand, the induction of place preference
with cannabinoid agonists and antagonists has been
reported in several studies [20-23]. Specifically, WIN
55212-2 induces CPP when administered peripherically
[13] or injected into the hippocampus [15]. We have no
knowledge of previous reports of cross-reinstatement
between a cannabinoid agonist-induced CPP and
MDMA. The strength of this reinstatement in the WIN-
induced CPP group was similar to that in the group
conditioned with MDMA, or even higher. Moreover,
more time was required for the reinstated preference to
be extinguished in mice conditioned with the cannabi-
noid agonist. The most important implication of the
cross reinstatement observed is that exposure to
MDMA can produce an intense craving and relapse to
drug-taking behavior in cannabinoid-dependent humans.
On the other hand, the MDMA-induced CPP was not
reinstated by priming injections of WIN (second experi-
ment). Thus, cross reinstatement was not observed in this
case. One possible justification for this lack of reciprocity
is that these drugs have a particular neurotransmitter acti-
vation profile. MDMA is a DA releaser that affects other
systems, such as the serotoninergic system, but cannabi-
noids seem to play a modulating role in DA transmission.
Another possible explanation is that, in animals condi-
tioned with MDMA, the first exposure to the cannabinoid
agonist induces an aversive effect that does not recall the
preference induced by MDMA. Conditioned place aver-
sion induced by WIN has previously been reported [24].
We have recently induced reinstatement of MDMA-
induced CPP by priming doses of WIN (0.1 mg/kg) in
mice previously exposed to this cannabinoid agonist [25],
which gives support to the latter hypothesis.
On the other hand, the CB1 agonist WIN exerted a
dual effect on the MDMA-induced CPP. The highest
WIN dose (0.5 mg/kg), which in itself induced CPP,
diminished preference when administered with an effec-
tive dose of MDMA (2.5 and 5 mg/kg). On the other
hand, a low dose of this CB1 agonist (0.1 mg/kg), inac-
tive when administered alone, strengthened the reward-
ing effects of an inactive dose of MDMA (1,25 mg/kg)
and induced CPP. Moreover, the time needed for the
preference to be extinguished was longer in the groups
treated with the lowest dose of WIN 55212-2. Our
results are in accordance with those of Robledo et al
[18], who reported that a sub-threshold dose of THC
p r o d u c e dC P Pi nm i c ew h e nc o m b i n e dw i t han o n -
rewarding dose of MDMA (3 mg/kg), but decreased the
CPP induced by an effective dose of MDMA (10 mg/kg).
Self-administration studies have also confirmed that
the endogenous cannabinoid system influences the
mechanism that regulates MDMA’s rewarding effect.
Braida and Sala [16] demonstrated that the cannabinoid
agonist CP 55,940 altered i.c.v. MDMA self-administra-
tion and significantly reduced MDMA intake, suggesting
a synergistic action of cannabinoid agonists on the
rewarding properties of MDMA. On the other hand, in
a report by Robledo et al [18], the heightened operant
response induced by the cannabinoid antagonist SR in
MDMA self-administration indicated a decrease in sen-
sitivity to the motivation for obtaining the drug. In addi-
tion, THC increased the threshold for MDMA when
self-administrated.
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mine synthesis, release and turnover [26]. The overlap-
ping expression of cannabinoid and dopamine receptors
in some brain areas, such as the NAC [27], may repre-
sent a neuroanatomical substrate for such an interac-
tion. The complex relation between cannabinoids and
MDMA is also observed in microdialysis studies of DA
release into the NAC. A low dose of THC was shown to
significantly increase DA outflow in the NAC, while a
low dose of MDMA did not. When MDMA was admi-
nistered before THC, DA levels were lower with respect
to those of THC. However, when THC was adminis-
tered before MDMA, DA levels were not significantly
modified with respect to those of THC [18]. If we apply
these results to our experiment in which both drugs
(MDMA and WIN) were administered together, we can
hypothesize that doses of MDMA or WIN that in them-
selves can increase DA release would exert an antago-
nistic action on DA; i.e, DA would not be released.
The cannabinoid-selective CB1 antagonist SR 141716
did not affect the CPP or reinstatement of the prefer-
ence induced by 5 mg/kg of MDMA when administered
alone or with WIN. In the groups conditioned with 1.25
mg/kg of MDMA, which was not effective by itself, CPP
was observed when administered with the CB1 antago-
nist. Moreover, when this sub-threshold dose of MDMA
was administered with 0.1 mg/kg of WIN, the CPP
induced was not affected by blockade of the CB1 recep-
tor. These results can be explained if the sense that the
CB1 cannabinoid agonist WIN exerts its effects in a way
that does not involve the CB1 receptors. Although WIN
is a CB1 receptor agonist, some of its effects seem to be
mediated by mechanisms that do not involve cannabi-
noid receptors, and which could be calcium-dependent
mechanisms [28]. On the hand, SR141716 is capable of
producing conditioned place preference in rats [29,21],
although studies performed in our laboratory failed to
detect an motivational action of this CB1 antagonist
[13]. In a similar way to WIN, SR 141716 is reported to
exhibit an independent CB1 activity; for instance, it
exerts an anxiolytic effect on CB1 knockout mice [30]
The aversive effects of cannabinoid agonists observed in
many studies, and the rewarding effect of cannabinoid
antagonists are suggestive of a cannabinergic tone in the
rat brain. Cannabinoid receptors, while present in areas
of the brain that support electrical self-stimulation, such
as the nucleus accumbens or the lateral septum [31], are
also localized in the central and basolateral amygdaloid
nuclei and in the periaqueductal gray, two areas that
support electrically-induced fear responses and are
thought to be the sites of action of certain anxiogenic
drugs. The observation by Herkenham and Brady [32]
that D9-THC induces c-Fos expression in stress-respon-
sive nuclei of the rat brain further supports an
anxiogenic role of cannabinoids. Recently, Wu and
co-workers [33] have demonstrated that SR141716A
employed at the dose used in the present study (3 mg/
kg, i.p.) produces an increase of DA release in the dorsal
and ventral striatum, although inhibition of dopamine
release induced by nicotine, ethanol, and cocaine has
been described for other authors [34]. The present data
suggest that endogenous cannabinoids both inhibit
reward and induce aversion by actions exerted within
these circuits [29].
The role of CB1 cannabinoid receptors in the reward-
ing effects of drugs of abuse is not altogether clear
[24,35-37]. Although SR reduces the acquisition of CPP
induced by cocaine, morphine or food in a dose-depend
manner, it does not affect the expression of the cocaine-
induced CPP [24]. More recently, studies performed in
CB1 knockout mice [38] have shown that they develop a
normal CPP despite the fact that many of the effects of
MDMA are diminished in these animals, among them
self-administration. The CB1 cannabinoid receptor is
essential in the acute rewarding effects of several drugs
of abuse that produce their effect on the ventral teg-
mental area, such as nicotine, ethanol and morphine.
However, psychostimulant drugs produce their effect
directly on the nucleus accumbens DA terminals [11].
For that reason, the CB1 cannabinoid receptor does not
seem to contribute to their acute rewarding effects
when evaluated in the CPP. Accordingly, previous stu-
dies have reported that cocaine-induced CPP but not
self-administration is preserved in CB1 knockout mice
[39]. In the study of Braida et al [17], SR blocked the
MDMA-induced CPP, although there are several and
important differences between this and the present
study, including the species used and the form of
MDMA administration (intracerebroventricular). More-
over, SR increased the rewarding effects of 1.25 mg/kg
MDMA. We can hypothesize that, when SR is adminis-
tered jointly with WIN, the antagonist blocks the CB1
receptor and in that way inhibits WIN action, while at
the same time decreasing the cannabinoid tone and
indirectly increasing the rewarding action of MDMA.
As we have previously observed [14], MDMA did not
affect the concentration of DA or serotonin, or their
metabolites in the striatum or cortex at the doses
employed during the CPP procedure. However, an
increase in serotonin concentration (5 mg/kg) and
decreases in the levels of 5-HIAA were observed in the
hippocampus. The CB1 agonist WIN did not affect the
brain monoamines, with the exception of an increase in
the level of 5-HIAA in the hippocampus with the lowest
dose (0.1 mg/kg). Nevertheless, in the striatum of the
animals treated with the highest doses of MDMA and
WIN, a decrease in the DA concentration (over 40%)
was observed. A reduction in cortical serotonin occurred
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with the highest dose of MDMA plus WIN 0.1 (in
which there was also an increase in the levels of
5-HIAA in the hippocampus) or the lowest dose of
MDMA plus the highest dose of WIN (over 20% of a
reduction of serotonin in both groups).
The anti-inflamatory and anti-oxidative properties of
cannabinoids point to their possible beneficial effects
with respect to limiting neurological damage, particu-
larly by decreasing neuroinflamation [40,41]. However,
animal studies have revealed that chronic administration
of the cannabinoid THC causes hippocampal damage
[42], and several reports have highlighted that exposure
to low concentrations of cannabinoids over a prolonged
period is likely to have a neurotoxic effect [43,44].
Acute administration at high concentrations of cannabi-
noids at the time of trauma, on the other hand, may be
neuroprotective. The decrease in striatal DA and cortical
serotonin in animals treated with 5 mg/kg of MDMA
plus the highest dose of WIN (0.5 mg/kg) could explain
the surprising lack of CPP observed in this group. With
a daily conditioning schedule we have seen that 5 mg/kg
of MDMA induces a similar decrease in cortical seroto-
nin and striatal DA and does not achieve preference in
the Post-C test [14]. However, these results should be
interpreted with caution, as the measurements were
obtained only 48 h after the last drug administration.
Conclusions
The results of the present study confirm that the canna-
binoid system plays a role in the rewarding effects of
MDMA. A high proportion of MDMA users also con-
sume cannabis, which makes the study of the interaction
between the two drugs highly relevant. Moreover, the
observed cross-reinstatement between these drugs high-
lights the importance of sporadic drug use in relapse to
dependence. To conclude, our results do not support a
neuroprotective action of cannabinoids; the present data
show that WIN 55212-2 induces a decrease in the con-
centrations of dopamine and serotonin in the striatum
and cortex 48 hours after administration in conjunction
with a non-neurotoxic dose of MDMA.
Additional file 1: Effects of MDMA or WIN administration on the
concentrations of monoamines (ng/mg tissue) in the striatum,
cortex and hippocampus.
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